LACTOLOGY FOUNDATION

Misoprostol (ATC A02BB01) is a synthetic prostaglandin E1 analogue used mainly for prevention of NSAID‑induced gastric ulcers and for various obstetric and gynecological indications, with important toxicological and lactation‑related considerations. It appears in breast milk in negligible amounts and is generally considered compatible with breastfeeding for short‑term use, although some product labels still recommend avoiding use during lactation because of theoretical risks such as infant diarrhea.

Pharmacology and therapeutic uses

Misoprostol is a synthetic analogue of prostaglandin E1 that reproduces the cytoprotective and antisecretory actions of endogenous gastroprotective prostaglandins. It reduces gastric acid secretion, increases mucus and bicarbonate production, and enhances mucosal blood flow, thereby lowering the risk of NSAID‑induced gastric ulceration.

Clinically, misoprostol is approved to reduce the risk of NSAID‑induced gastric ulcers in high‑risk patients and is also available in fixed‑dose combination with diclofenac for osteoarthritis and rheumatoid arthritis. Off‑label and obstetric/gynecologic uses include medical termination of pregnancy (usually in combination with mifepristone), management of miscarriage, cervical ripening, induction of labor, and prevention or treatment of postpartum hemorrhage. Additional less common off‑label applications described include NSAID‑induced nephropathy, treatment of fat malabsorption in cystic fibrosis, and pharmacologic cervical dilation.

Pharmacokinetics and toxicology

After oral administration misoprostol is rapidly and almost completely absorbed from the gastrointestinal tract and undergoes extensive first‑pass hepatic metabolism to the active free acid (misoprostol de‑esterified metabolite).* Peak plasma concentrations of the active metabolite occur within about 30 minutes, and the elimination half‑life is approximately 20–40 minutes. Excretion is predominantly renal, with about 70–85% of the administered dose recovered in urine and the remainder in feces.

Toxicologically, misoprostol exerts dose‑dependent stimulation of uterine smooth muscle, which can lead to uterine contractions, cervical softening, bleeding, and pregnancy loss; therefore it is contraindicated in pregnancy for gastroprotection and carries pregnancy category X labeling. Common adverse effects include headache, dizziness, nausea, vomiting, abdominal pain, and diarrhea, the latter often dose‑related and reduced when the drug is taken with food. Other reported adverse reactions include constipation, uterine hyperstimulation and metrorrhagia, skin reactions, blood pressure fluctuations, and in rare post‑marketing reports, neonatal complications including sudden death when exposure occurred via maternal treatment.

Overdose can intensify gastrointestinal and uterine adverse effects and may manifest with severe diarrhea, abdominal cramping, uterine contractions, uterine hemorrhage, hypotension, and altered consciousness; management is symptomatic and supportive because there is no specific antidote. Use requires particular caution in patients with renal, cardiovascular, or neurologic disease due to altered pharmacokinetics and the potential hemodynamic effects of prostaglandins.

Use during pregnancy

Misoprostol is strongly contraindicated in pregnancy when used solely for gastric protection because it can cause uterine contractions, cervical ripening, and pregnancy termination or congenital anomalies. Teratogenic outcomes associated with misoprostol exposure in early pregnancy include Möbius sequence, limb defects, and other cranial nerve abnormalities, presumably due to uterine contractions and vascular disruption.

For intentional medical abortion or medical management of miscarriage, misoprostol is deliberately used, usually with mifepristone, in carefully controlled regimens and settings. In this context the toxicological risk is weighed against the therapeutic objective, and counseling should explicitly address uterine risks, bleeding, infection, and the need for emergency access to care.

Lactation safety and TOXYLACT perspective

Misoprostol and its active acid are excreted into breast milk in very low concentrations, and available data suggest that infant exposure is negligible at usual single or short‑course doses (up to about 600 micrograms). Lactation references such as LactMed and national specialist pharmacy services state that, because of the low milk levels and rapid elimination, clinically significant effects in breastfed infants are unlikely, and breastfeeding does not need to be interrupted following maternal misoprostol given by any route.

Nevertheless, several product monographs and manufacturers advise against use during breastfeeding, citing the potential for misoprostol acid in milk to cause infant diarrhea and referring to post‑marketing reports of serious neonatal outcomes. The local TOXYLACT classification assigns misoprostol a toxicolactational category IV, indicating a drug considered incompatible with breastfeeding, based on a plasma‑to‑milk ratio approximating 1:1 and concern for severe diarrhea and rare serious neonatal adverse events. In contrast, contemporary evidence‑based lactation guidance generally considers misoprostol compatible with breastfeeding when used as a single dose or short course, with the precaution of clinical observation of the infant for gastrointestinal symptoms such as diarrhea, vomiting, and poor feeding, especially in neonates or medically fragile infants.

In practical clinical decision‑making, risk–benefit assessment should consider: indication and urgency (e.g. postpartum hemorrhage, medical abortion), dosing regimen (single vs repeated doses), infant age and health, and the availability of safer alternatives for purely gastroprotective purposes in lactating women. Where misoprostol is essential (for example, for medical abortion or life‑saving obstetric indications), most modern guidelines support continuation of breastfeeding without interruption, with infant monitoring rather than automatic cessation of lactation.

Regulatory and risk classification

From a regulatory standpoint, misoprostol is labeled as pregnancy category X and carries boxed warnings about its abortifacient potential when used in women of childbearing potential. Gastroprotective indications specifically exclude pregnant women, and strict measures are recommended to prevent inadvertent use in early pregnancy (including patient education and contraception).

For lactation, official product information is heterogeneous: some manufacturers contraindicate use during breastfeeding or recommend avoidance, while others advise only caution in nursing mothers due to theoretical risk of diarrhea in the infant. TOXYLACT locally categorizes misoprostol as a category IV drug, deemed incompatible with breastfeeding, emphasizing a precautionary toxicological stance aimed at minimizing neonatal exposure to prostaglandin analogues via milk.